Related Experiment Video

Updated: Jul 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

New agents for treatment of advanced transitional cell carcinoma

F G E Perabo1, S C Müller

  • 1Department of Urology, University Hospital, Bonn, Germany. perabo@lycos.com

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 5, 2006
PubMed

Insights

New chemotherapies and targeted agents offer hope for advanced urothelial cancer. Research focuses on improving survival and reducing side effects for patients with invasive transitional cell carcinoma.

Area of Science:

  • Oncology
  • Urothelial Carcinomas
  • Chemotherapy

Background:

  • Prognosis for progressive/recurrent invasive transitional cell carcinoma is poor.
  • Cisplatin-based chemotherapy is standard for metastatic urothelial cancer, but response rates are limited and side effects severe.
  • High relapse rates necessitate novel, tolerable treatment options.

Purpose of the Study:

  • To review emerging chemotherapeutic and molecularly targeted agents for invasive urothelial cancers.
  • To highlight agents with potential to improve patient survival and treatment tolerability.

Main Methods:

  • Literature review of recent clinical research in urothelial carcinoma treatment.
  • Focus on novel chemotherapeutic agents and molecularly targeted therapies.
  • Analysis of response rates, survival data, and side effect profiles.

Main Results:

  • New platinum compounds (oxaliplatin, lobaplatin) show activity.
  • Antifolates (piritrexim, pemetrexed) and vinflunine are under investigation.
  • Molecularly targeted agents include farnesyltransferase inhibitors, ribozymes, HDAC inhibitors, and monoclonal antibodies.

Conclusions:

  • Significant unmet need exists for improved treatments for advanced urothelial cancer.
  • Emerging agents show promise in overcoming limitations of current therapies.
  • Further research is crucial to develop more effective and tolerable treatments for patients.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.